Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee

NCT03291470 is registered in ClinicalTrials.gov with Kolon TissueGene, Inc. as lead sponsor.

NCT NCT03291470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03291470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee
Lead sponsor
Kolon TissueGene, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 9, 2021
Completion date
May 1, 2026
Enrollment
531 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative osteoarthritis